• Fatih Alagöz, Mert Şahinoğlu, Deniz Billur, Sevim Aydın, Rıfat Akdağ, Durmuş Oğuz Karakoyun, and Ergün Daglıoğlu.
• Department of Neurosurgery, University of Health Sciences, Bilkent City Hospital, Ankara-Turke.
• Ulus Travma Acil Cer. 2022 Mar 1; 28 (3): 242248242-248.

BackgroundGalantamine is well-known for its neuroprotective effects and is currently used in the treatment of individuals with Alzheimer's disease. In this study, we induced experimental sciatic nerve injury (SCI) in rats to test the beneficial effects of galantamine.MethodsThirty male Wistar albino rats were divided into three groups, as follows: sham, SCI + saline, and SCI + galantamine. After the administration of an intraperitoneal ketamine and xylazine mixture, which was used for anesthesia, SCI was induced by sur-gical clip compression at the midthigh region of the rats. After surgery, a single daily intraperitoneal dose of galantamine was adminis-tered for 7 days, and nerve tissue sections were obtained 1 week after injury. Histopathology studies were performed to assess neural thickness and apoptotic cell counts, and light microscopic morphological examination was used to determine a potential beneficial effect of galantamine on peripheral nerve degeneration.ResultsWe observed a markedly increased microvasculature, increased nerve fiber thickness, and a statistically significant increase in apoptotic cell counts distal to the level of injury in the saline group compared with the sham group. However, the increases in nerve fiber thickness and apoptotic cell counts were less in the galantamine group compared with the saline group.ConclusionIn our experimental model, pharmacological intervention with galantamine demonstrated a protective effect on degeneration after peripheral nerve injury.

13 keywords...

hide…